Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis

 描述（由申请人提供）：加州大学戴维斯分校保罗卡拉布雷西K12临床肿瘤学研究职业发展计划（CDP; PI，Primo Lara，Jr.）的总体目标。医学博士）是培养临床医生或基本翻译初级教师成为独立的，以病人为导向的癌症研究人员谁是高度培训的翻译，团队驱动的研究。使用1）核心能力，2）先进的肿瘤学课程，3）职业发展，4）指导研究，5）跨文化接触，CDP每年提供两名新学者（任何时候六名），旨在磨练远远超出其最初学科界限的想法和技能的培训。学者将克服临床和基础翻译研究人员之间通常存在的语言和文化障碍，利用加州大学戴维斯分校的合作研究环境，参加多学科和翻译论坛，并收集研究设计，临床试验开发，团队科学，授予写作研究，沟通和职业发展的道德行为的基本技能。其愿景是通过培训临床研究人员将基础/相关科学纳入并利用临床试验（“临床轨道”）来加强转化研究，反过来，推动基础科学家进行患者驱动的药物开发和临床研究（“基础/转化轨道”）。为了保持对患者驱动的临床研究的重视，所有CDP学者在临床导师和基本/翻译导师的指导下，将被要求在培训期间开发和启动/进行自己的临床试验。该计划将利用NCI指定的UC Davis综合癌症中心，NCATS资助的临床和转化研究中心（CTSC）和医学职业发展计划的学校的优秀研究，培训和评估专业知识和基础设施。它将由一个组织严密的内部监督委员会和外部咨询委员会监督和加强。总体而言，CDP旨在实现以下具体目标：1）提供基于能力的教学课程，以促进团队科学，鼓励转化研究，并磨练临床试验开发的基本技能 职业/研究成功; 2）监督个性化的以患者为导向的研究项目，以满足每位学者的兴趣和需求;以及3）监督学者培训，以确保逐步培养一批完全胜任的跨学科研究人员，他们可以成功地使用研究性新药或器械进行转化癌症临床试验。这些具体的目标将使训练有素的研究人员在加州大学戴维斯分校的创新，有影响力的，以证据为基础的研究的前沿，谁可以监督研究，包括从基础科学（目标识别和药物发现）通过转化科学（药物开发和相关科学）的研究的整个连续体的建设临床调查。通过这样做，我们提供了潜在的 既能提高临床科学家的成功率，又能改善癌症患者的预后。

 DESCRIPTION (provided by applicant): The overarching goal of the UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program (CDP; PI, Primo Lara, Jr. MD) is to nurture clinician or basic-translational junior faculty to become independent, patient-oriented cancer researchers who are highly trained in translational, team-driven research. Using 1) core competencies, 2) advanced oncology coursework, 3) career development, 4) mentored research, and 5) cross-cultural exposure, the CDP provides two new scholars per year (six at any one time) with training aimed at honing ideas and skills that go far beyond their initial disciplinary boundaries. Scholars will overcome language and cultural barriers that typically exist between clinical and basic-translational researchers, take advantage of the collaborative research environment at UC Davis, participate in multidisciplinary and translational forums, and gather essential skills in research design, clinical trial development, team science, grant writing ethical conduct of research, communication, and career development. The vision is to enhance translational research by training clinician researchers to incorporate and utilize basic/correlatie science in their pursuit of clinical trials ("Clinical Track"), and conversely, driving basic scienists towards patient-driven drug development and clinical research ("Basic/Translational Track"). To maintain the emphasis on patient- driven clinical research, all CDP scholars, under the mentorship of both a clinical mentor and basic/translational mentor, will be required to develop and initiate/conduct their own investigator-initiated clinical trial during the training period. Th program will leverage the outstanding research, training, and evaluation expertise and infrastructure of the NCI-designated UC Davis Comprehensive Cancer Center, NCATS-funded Clinical and Translational Research Center (CTSC), and School of Medicine Career Development Program. It will be overseen and enhanced by a highly organized internal Oversight Committee and external Advisory Board. Overall, the CDP seeks to accomplish the following specific aims: 1) Offer a competency-based didactic curriculum to promote team science, encourage translational research, and hone essential skills for clinical trial development and career/research success; 2) Oversee individualized patient- oriented research projects customized to the interests and needs of each scholar; and 3) Provide oversight of scholar training to ensure the progressive development of a cadre of fully competent interdisciplinary-oriented researchers who can successfully conduct translational cancer clinical trials with investigational new agents or devices. These specific aims will enable the building of a critical mass of trained researchers at UC Davis at the forefront of innovative, impactful, evidence-based research, who can oversee research that encompasses the entire continuum of research from basic science (target identification and drug discovery) through translational science (drug development and correlative science) to clinical investigation. By doing so, we offer the potential of both enhancing the success of clinician scientists and improving outcomes for cancer patients.